PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15606443-1	2005	AIMS: Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8.	Rosiglitazone	6-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-167	
15606443-1	2005	AIMS: Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme CYP2C8.	Rosiglitazone	6-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	169-172	
17178266-1	2006	OBJECTIVES: Rosiglitazone is metabolically inactivated predominantly via the cytochrome P450 (CYP) enzyme CYP2C8.	Rosiglitazone	12-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	77-92	
17178266-1	2006	OBJECTIVES: Rosiglitazone is metabolically inactivated predominantly via the cytochrome P450 (CYP) enzyme CYP2C8.	Rosiglitazone	12-25	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	94-97